Neurovascular Product Articles & Analysis
15 news found
Balt, an innovative neurovascular company focused on developing, designing, and manufacturing solutions for treating complex, life-threatening conditions, including stroke, aneurysms, and arteriovenous malformations, today announced the appointment of Jeffrey Sachs as the Company's Chief Legal & Compliance Officer. ...
Balt, an innovative neurovascular company focused on developing, designing, and manufacturing solutions for treating complex, life-threatening conditions, including stroke, aneurysms, and arteriovenous malformations, today announced enrollment in the FIRST study has been completed. ...
Food and Drug Administration (FDA) has approved its Investigational Device Exemption (IDE) application to conduct a U.S. trial for the Contour Neurovascular System™, indicated for the treatment of intracranial aneurysms. ...
Food and Drug Administration (FDA) for its Contour Neurovascular System™. Breakthrough Device Designation is granted to medical devices and device-led combination products that provide the potential for a more effective treatment option for life threatening or irreversibly debilitating diseases. ...
Stephen Griffin, President of Cerus Endovascular, stated, "Given the significant advances made in robotic assisted surgical technologies in recent years and the many advantages they bring to interventional medicine, this successful robotic assist implant represents a significant milestone in our company's history and should serve to expand awareness for, and use of, the Contour device. We ...
“The STEM study represents the first of several PMA trials planned in the next 12 to 18 months, delivering on the promise to bring Balt’s portfolio of innovative and novel products into the US market.” About Balt: Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening ...
“Our partnership with Balt, an internationally-recognized pioneer in the neurovascular sector, reflects the strength of our innovative product line and will provide significantly increased awareness and more rapid penetration of both the Contour Neurovascular System™ and the Neqstent device within Germany, the largest market within ...
We are extremely pleased by the response of the medical community to our product portfolio.” About the CerusEndo MC 021 Microcatheter The CerusEndo MC 021 microcatheter, which already received approval from the U.S. ...
Balt CEO Pascal Girin commented, “Balt has provided physicians for decades with unique, life-saving products to treat patients with neurovascular conditions and has been a pioneer in flow diversion technologies. ...
” About Balt: Since it was established in 1977, Balt has worked with interventional physicians to develop devices to treat complex life-threatening neurovascular conditions such as ischemic strokes, aneurysms and arteriovenous malformations. A pioneer in the neurovascular field, Balt designs, manufactures and distributes the broadest portfolio of ...
“In response to numerous requests from the clinical community and physicians we work closely with, we continue to aggressively expand our product portfolio to offer an even more comprehensive suite of products to meet market needs, complementing our Contour 027 device and Neqstent platform, which recently received CE Mark approval,” stated Dr. ...
” “Once again our remarkable team of dedicated professionals continue to widen and diversify our product portfolio to bring critical products to market, helping to position Cerus as a key solution provider within the industry,” stated Dr. ...
Completion of the Series B financing will allow the company to execute on its go-to-market strategy and to complete the planned expansion of its product portfolio, which will include a smaller delivery platform for its recently CE Marked lead product, the Contour Neurovascular System, for the treatment of intracranial aneurysms. ...
Nelson brings more than three decades of experience as a medical device executive and has extensive background in new product development, marketing and commercialization. Prior to Q’Apel, Nelson served as President and CEO of Uptake Medical, Kerberos Solutions and VenPro Cardiovascular. The walrus BGC represents the second FDA-cleared technology from Q’Apel in the ...
Food and Drug Administration (FDA) 510(k) clearance of its first family of access catheters, designed to deliver interventional treatments during minimally invasive neurovascular procedures for aneurysms, stroke and other brain blood vessel conditions. ...